Literature DB >> 11470045

The antiphospholipid syndrome and infection.

G N Dalekos1, K Zachou, C Liaskos.   

Abstract

Infectious agents have been implicated in the induction of antiphospholipid (aPL) antibodies and the development of the antiphospholipid syndrome (APS). This review focuses on the types of aPL antibodies detected in infections and addresses whether these antibodies are of clinical importance in patients with infections. Hepatitis C virus (HCV) infection is given special attention because this virus has the propensity to induce various autoimmune phenomena. Several aspects are emphasized that should be considered carefully when interpreting results. Most of the published data agree that thrombophilia is not observed in patients with infections (including HCV) because aPL antibodies are mostly the natural or nonpathogenic type. Thus, we do not recommend routinely testing for HCV in patients with APS. However, not all infection-associated aPL antibodies are cofactor independent. For instance, infections are increasingly recognized as a major precipitating condition of the catastrophic variant of APS, perhaps via mechanisms of molecular mimicry. Therefore, it may be possible to prevent this devastating evolution if the infectious process is promptly recognized and exhaustively treated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470045     DOI: 10.1007/s11926-001-0031-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  52 in total

Review 1.  Antiphospholipid antibodies.

Authors:  H P McNeil; S A Krilis
Journal:  Aust N Z J Med       Date:  1991-08

2.  High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications.

Authors:  M Harada; Y Fujisawa; S Sakisaka; T Kawaguchi; E Taniguchi; M Sakamoto; S Sumie; K Sasatomi; H Koga; T Torimura; T Ueno; K Gondo; H Yoshida; K Tanikawa; M Sata
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

3.  Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.

Authors:  C Petrovas; P G Vlachoyiannopoulos; T Kordossis; H M Moutsopoulos
Journal:  J Autoimmun       Date:  1999-11       Impact factor: 7.094

4.  Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia.

Authors:  P Giordano; M Galli; G C Del Vecchio; M Altomare; F Norbis; L Ruggeri; M Petronelli; D de Mattia
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

Review 5.  New developments in viral peptides and APL induction.

Authors:  A E Gharavi; S S Pierangeli; E N Harris
Journal:  J Autoimmun       Date:  2000-09       Impact factor: 7.094

6.  Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury.

Authors:  C Biron; H Andréani; P Blanc; J Ramos; J Ducos; N Guigue; H Michel; D Larrey; J F Schved
Journal:  J Lab Clin Med       Date:  1998-03

7.  High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha.

Authors:  J Matsuda; N Saitoh; M Gotoh; K Gohchi; M Tsukamoto; S Syoji; K Miyake; M Yamanaka
Journal:  Am J Gastroenterol       Date:  1995-07       Impact factor: 10.864

Review 8.  Diagnosis of the antiphospholipid syndrome: a proposal for use of laboratory tests.

Authors:  E N Harris; S S Pierangeli; A E Gharavi
Journal:  Lupus       Date:  1998       Impact factor: 2.911

Review 9.  Origin of antiphospholipid antibodies: induction of aPL by viral peptides.

Authors:  A E Gharavi; S S Pierangeli
Journal:  Lupus       Date:  1998       Impact factor: 2.911

10.  Mycoplasma penetrans bacteremia and primary antiphospholipid syndrome.

Authors:  A Yáñez; L Cedillo; O Neyrolles; E Alonso; M C Prévost; J Rojas; H L Watson; A Blanchard; G H Cassell
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

View more
  9 in total

Review 1.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.

Authors:  R Cervera; R A Asherson; M L Acevedo; J A Gómez-Puerta; G Espinosa; G De La Red; V Gil; M Ramos-Casals; M García-Carrasco; M Ingelmo; J Font
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

2.  Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome.

Authors:  Eirini I Rigopoulou; Kalliopi Zachou; Nikolaos K Gatselis; Georgia Papadamou; George K Koukoulis; George N Dalekos
Journal:  World J Hepatol       Date:  2013-10-27

3.  Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study.

Authors:  Nikolaos K Gatselis; Sarah P Georgiadou; Nikolaos Tassopoulos; Kalliopi Zachou; Christos Liaskos; Angelos Hatzakis; Georgios N Dalekos
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

4.  IgA anti-b2GPI antibodies in patients with autoimmune liver diseases.

Authors:  Stella Gabeta; Gary L Norman; Nikolaos Gatselis; Christos Liaskos; Panagiotis A Papamichalis; Athanasios Garagounis; Kalliopi Zachou; Eirini I Rigopoulou; George N Dalekos
Journal:  J Clin Immunol       Date:  2008-06-13       Impact factor: 8.317

5.  Characterization of antiphospholipid antibodies in chronic hepatitis B infection.

Authors:  Ji Young Huh; Dae Young Yi; Seong Gyu Hwang; Jin Jung Choi; Myung Seo Kang
Journal:  Korean J Hematol       Date:  2011-03-15

6.  Multiple autoimmune propensity and B-non-hodgkin lymphoma: cause or effect?

Authors:  E Koumati; M Palassopoulou; P Matsouka; A Polyzos; G N Dalekos; K Zachou
Journal:  Autoimmune Dis       Date:  2011-05-03

7.  Effect and mechanism of the aβ2‑GP I/rhβ2‑GP I complex on JEG‑3 cell proliferation, migration and invasion.

Authors:  Xiumin Lu; Lei Ren; Wenjing Zhang; Yanhong Liu
Journal:  Mol Med Rep       Date:  2018-03-29       Impact factor: 2.952

8.  Ocular disorders as the prevailing manifestations of antiphospholipid syndrome: a case series.

Authors:  Evangelia Tsironi; Nikolaos Gatselis; Maria G Kotoula; Kalliopi Zachou; Maria Pefkianaki; Fani Zacharaki; Dimitrios Z Chatzoulis; George N Dalekos
Journal:  Cases J       Date:  2009-10-20

Review 9.  Antiphospholipid syndrome infectious origin.

Authors:  M Blank; R A Asherson; R Cervera; Y Shoenfeld
Journal:  J Clin Immunol       Date:  2004-01       Impact factor: 8.542

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.